We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gray Areas in Parenteral Drug Labeling a Cause for Concern
Gray Areas in Parenteral Drug Labeling a Cause for Concern
February 5, 2007
Regulations established by the FDA and the United States Pharmacopeia (USP) for labeling parenteral infusion drug products leave significant gray areas that may put patients at risk, according to experts speaking at a recent NIH conference.